论文部分内容阅读
目的 观察缬沙坦对慢性乙型肝炎 (简称慢肝 )、肝硬化患者的临床治疗效果 ,探讨其作用机制。方法 54例慢肝、肝硬化患者随机分为对照组与治疗组 ,对照组给予常规治疗 ,治疗组在常规治疗的基础上加用缬沙坦 80mg/d ,疗程 1个月。两组患者于治疗前后抽血测肝功能、血清一氧化氮 (NO)、内皮素 (ET)等指标 ,了解治疗前后肝功能、血管活性因子的变化。结果 治疗组经缬沙坦治疗后肝功能ALT、AST明显好转 ,血清ET降低 ,NO升高。以上指标与对照组相比差异有显著性 (P <0 0 5)。结论 缬沙坦治疗慢肝、肝硬化患者能够发挥一定的保护肝细胞及血管内皮细胞 ,改善肝脏微循环的作用
Objective To observe the clinical effect of valsartan on patients with chronic hepatitis B (chronic liver disease) and cirrhosis and to explore its mechanism. Methods 54 patients with chronic liver cirrhosis were randomly divided into control group and treatment group. The control group was given routine treatment. The treatment group received valsartan 80 mg / d on the basis of routine treatment for one month. Before and after treatment, the two groups of patients were tested for liver function, serum nitric oxide (NO), endothelin (ET) and other indicators before and after treatment to understand the changes of liver function and vasoactive factors before and after treatment. Results After treatment with valsartan, ALT and AST of liver function were improved obviously, serum ET decreased and NO increased. The above indicators compared with the control group, the difference was significant (P <0 05). Conclusion Valsartan in patients with chronic liver cirrhosis can play a certain role in protecting liver cells and vascular endothelial cells, improve liver microcirculation